ArticleJournal of the American Society of Nephrology : JASN2026
A Five-Plasma Protein-Based Algorithm for Predicting Incident CKD in Type 2 Diabetes.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a predictive model for diabetic kidney disease risk in patients with T2DM: a hospital data platform study.Frontiers in endocrinology · 2026Article
- Quantitative Proteomics: Recent Advances in Glomerular Disease and Nephrotic Syndrome.Glomerular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
key pointsProteomics analyses consistently identified nine independent protein predictors for CKD in both Chinese and European participants with type 2 diabetes. A novel prediction model, "eGFR+five-protein panel predicting CKD," reliably predicted CKD with good performance (area under the receiver operating characteristic curve ≥0.80). The new "eGFR+five-protein panel predicting CKD" model exhibited superior performance over traditional clinical models.
backgroundCurrently, there is a lack of reliable biomarkers for noninvasive prediction of CKD in patients with diabetes. This study aimed to identify novel protein predictors and construct a prediction model for incident CKD in participants with type 2 diabetes applicable across different populations.
methodsA targeted Olink plasma proteomics profiling analysis, involving 368 proteins, was conducted in a nested case-control study comprising 132 incident CKD cases and 132 non-CKD controls, matched for age, sex, duration of diabetes, and eGFR, recruited from a long-term prospective cohort of Chinese type 2 diabetes participants (median approximately 9-year follow-up). False discovery rate was applied for multiple testing corrections. A q -value <0.2 was considered statistically significant. Three machine-learning approaches (Boruta, support vector machine, and eXtreme gradient boosting) were used for feature selection. Independent associations of proteins with incident CKD with adjustments for conventional clinical risk factors were examined in the training set ( n =1580, including 173 incident CKD cases and 1407 non-CKD controls; 70%) of the UK Biobank Pharma Proteomics Project (UKB-PPP) (median approximately 13.5-year follow-up). The least absolute shrinkage and selection operator-based Cox-regression analysis was used to develop the prediction model, which was subsequently validated in the testing set ( n =677, including 85 incident CKD cases and 592 non-CKD controls; 30%) of UKB-PPP.
resultsAmong the 18 identified protein features predictive of incident CKD, 12 showed significant associations with consistent direction of effects in both cohorts. A prediction model ("eGFR+five-protein panel predicting CKD [eGFR+FPPC]") combining eGFR and five proteins (α-1-microglobulin/bikunin precursor, matrix metallopeptidase 7, placental growth factor, TNF-related apoptosis-inducing ligand receptor 2, and kidney injury molecule-1) was constructed and validated in the testing and training sets of the UKB-PPP, respectively. The "eGFR+FPPC" model achieved superior predictive performance in both training (area under the receiver operating characteristic curve [95% confidence interval]: 0.82 [0.79 to 0.85]) and testing (area under the receiver operating characteristic curve [95% confidence interval]: 0.80 [0.74 to 0.86]) sets of UKB-PPP and yielded fewer indeterminate results compared with conventional clinical models.
conclusionsThe "eGFR+FPPC" model performed better than conventional clinical models in predicting incident CKD in type 2 diabetes participants across different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.